Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess safety and tolerability of escalating doses of a genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP vaccine following primary experimental challenge with P. falciparum sporozoites. Lastly, the study will assess immunogenicity of p52-/p36- GAP in malaria-naïve healthy adults and preliminary efficacy of p52-/p36- GAP vaccine following primary experimental re-challenge with P. falciparum sporozoites.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

NCT03168854

Plasmodium Falciparum Infection

COMPLETED PHASE1

Clinical Trial of the PfSPZ Vaccine

NCT01001650

Plasmodium Falciparum

COMPLETED PHASE1

Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes

NCT02313376

Malaria

COMPLETED PHASE1

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

NCT02015091

Malaria

COMPLETED PHASE1

Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults

NCT01540474

Malaria

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

p52-p36- GAP Vaccine

p52-/p56- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.

p52-/p56- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.

Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.

Group Type EXPERIMENTAL

p52-/p36- GAP Vaccine

Intervention Type BIOLOGICAL

Administered by five bites from GAP-infected Anopheles mosquito

p52-p36- GAP Vaccine

Intervention Type BIOLOGICAL

Administered by 200 bites from GAP-infected Anopeles mosquito

Infectivity Control

Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum

Group Type NO_INTERVENTION

No interventions assigned to this group

p52-p36- GAP Vaccine + Infectivity Challenge

p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.

Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum.

Group Type EXPERIMENTAL

p52-/p36- GAP Vaccine

Intervention Type BIOLOGICAL

Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

p52-/p36- GAP Vaccine

Administered by five bites from GAP-infected Anopheles mosquito

Intervention Type BIOLOGICAL

p52-p36- GAP Vaccine

Administered by 200 bites from GAP-infected Anopeles mosquito

Intervention Type BIOLOGICAL

p52-/p36- GAP Vaccine

Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of enrollment
* Free of significant health problems as established by medical history, laboratory assessment and clinical examination before entering into the study
* Volunteers must have low cardiac risk factors according to the NHANES I criteria and a non-significant electrocardiogram (EKG) as determined by a expert consultant cardiologist
* Available to participate for duration of study
* Reproductive status: a female participant must:
* not be of reproductive potential: i.e. be surgically, medically or physiologically sterile, or
* if engages in sexual activity that could lead to pregnancy:
* agrees to consistently use contraception until 2 months after the last protocol visit. Contraception is defined as using 1 of the following methods:
* condoms (male or female) with or without a spermicide
* diaphragm or cervical cap with spermicide
* intrauterine device (IUD)
* hormonal contraception
* If the volunteer indicates he/she is active duty military (on the DCT sign-in page and intake form), approval from their supervisor through the Division Director using the Statement of Supervisor's Approval Form must be signed and on file prior to receipt of any test product
* Written informed consent must be obtained from the subject before screening procedures
* Prior to entry into this study, subjects must score at least 80% correct on a 10- question multiple-choice quiz that assesses their understanding of this study.

Exclusion Criteria

* Prior receipt of any investigational malaria vaccine
* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period
* Administration of any vaccine within 30 days of first study vaccination Any past history of malaria
* Planned travel to malarious areas during the study period
* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection
* A family history of congenital or hereditary immunodeficiency
* Moderate or high 5-year cardiovascular risk as determined by NHANES 1 model
* An abnormal 12-lead electrocardiogram (EKG) suggestive of cardiac disease as determined by a clinician
* Seropositive for HIV, Hepatitis C virus (antibodies to HCV) and/or HBsAg
* Hepatomegaly, right upper quadrant abdominal pain or tenderness
* History of splenectomy
* Chronic or active neurologic disease including seizure disorder and chronic migraine headaches
* History of psoriasis and porphyria
* Acute or chronic, clinically significant pulmonary, cardiovascular, ocular, hematologic, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests and medical history review
* Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination. For corticosteroids, this is defined as prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed.
* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
* Current chronic use of medications known to cause drug reactions with chloroquine and/or atovaquone/proguanil such as cimetidine and metoclopramide.
* Current chronic use or use within one month prior to enrollment of antibiotics with anti-malarial effects such as tetracyclines for acne, sulfa drugs for recurrent urinary tract infections, etc.
* Pregnant or lactating female
* Female who is willing or intends to become pregnant during the study and for two (2) months after study completion
* Any history of allergic reaction or anaphylaxis to previous vaccination
* History of severe reactions to mosquito bites.
* Inability to make follow-up visits or complete diary cards
* Suspected or known current alcohol abuse/drug abuse as obtained by history and physical examination
* Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes